Liposomal Formulation of Lapatinib for the Treatment of Breast Cancer

Abstract

Breast cancer is the most common type of cancer among global women, even though numerous treatment options for breast cancer have been documented. Lapatinib, a tyrosine kinase inhibitor, modifies the cellular pathways and halts cell proliferation. The focus of this study includes the distribution of the drug to the tumor site in high amount and boost the efficiency of Lapatinib-loaded liposomes as a controlled drug delivery system against breast cancer. The synthesis of liposomes was followed by drug loading. The cargo was characterized under XRD, FTIR, SEM, EDX, and zeta analysis techniques. The overall findings demonstrated that the Liposomal formulation of Lapatinib has a high potential for sustained release of the drug for cancer therapy. As the successfully synthesized Lapatinibliposomes were stable and exhibited increased in vitro anticancer activity as compared to free Lapatinib. Our study demonstrates that the combination of Lapatinib with liposomes improves the drug's long-term viability, effectiveness, and active targeting as a potential targeted therapeutic molecule for breast cancer treatment. To strengthen the utilization of this combination therapy in cancer therapy trials, further research is warranted.